Patrizia CORNACCHIONE, Valentina LANCELLOTTA, Luca TAGLIAFERRI, Gian Carlo MATTIUCCI, Vincenzo VALENTINI, Mariangela MASSACCESI, Lucia CERVONE, Antonio PIRAS, Sebastiano MENNA, Luigi AZARİO, Maria ANTONIETTA GAMBACORTA

Hydrogel Spacer may Allow Prostate Re-irradiation even in Patients with Ulcerative Colitis: A Case Report

Salvage radiotherapy is a valid option for locally recurrent prostate cancer (PC) patients. Two of thetreatment options are as follows: interventional radiotherapy or stereotactic body radiotherapy (SBRT).SBRT has the main advantage as a noninvasive procedure. Synthetic gel injection into the prostate andrectum space, as a novel technique in prostate radiotherapy, spares the anterior rectal wall from a highdose. Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis (UC), contraindicateexternal beam radiotherapy due to increased bowel complication risk. In this study, we describe the firstPC patient with UC in remission treated with salvage SBRT and hydrogel rectal spacer. After ten monthsof follow-up, no bowel symptoms were reported, and SBRT provided both biochemical and clinical response. Even patients with UC and radio-recurrent PC may be viable salvage SBRT candidates.

PDF

___

1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008;112(2):307−14.
2. Haj-Hamed M, Karivedu V, Sidana A. Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies. Int Urol Nephrol 2019;51(7):1101−6.
3. Leroy T, Lacornerie T, Bogart E, Nickers P, Lartigau E, Pasquier D. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol 2017;12(1):95.
4. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, et al. Robotic imageguided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):889−97.
5. Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol 2015;5(6):e615−23.
6. Fiorentino A, Giaj Levra N, Mazzola R, Fersino S, Ricchetti F, Ballario R, et al. Stereotactic body radiation therapy with hydrogel spacer: a salvage reirradiation strategy for prostate cancer recurrence. Minerva Urol Nefrol 2016;68(5):464−6.
7. Tromp D, Christie DR. Acute and late bowel toxicity in radiotherapy patients with inflammatory bowel disease: a systematic review. Clin Oncol(R Coll Radiol) 2015;27(9):536−41.
8. Kovács G, Tagliaferri L, Valentini V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy 2017;9(6):497−8.
9. Montoya J, Gross E, Karsh L. How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy. Can J Urol 2018;25(2):9288−93.
10.SABR UK Consortium. Stereotactic ablative body radiation therapy (SABR): a resource. 2016. Available from: https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019- v6.1.0.pdf
11.Abusaris H, Storchi PR, Brandwijk RP, Nuyttens JJ. Second re-irradiation:efficacy, dose and toxicity in patients who received three courses of radiotherapy with overlapping fields. Radiother Oncol 2011;99(2):235−9.
12.Murphy CT, Heller S, Ruth K, Buyyounouski MK, Weinberg D, Uzzo RG, et al. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Pract Radiat Oncol 2015;5(3):e215−22.
13.Ruciński A, Bauer J, Campbell P, Brons S, Unholtz D, Habl G, et al. Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HIT. Radiat Oncol 2013;8:134.
14.Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.Int J Radiat Oncol Biol Phys 2015;92(5):971−77.
15.Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys 2017;97(5):976−85.
16.Karsh LI, Gross ET, Pieczonka CM, Aliotta PJ, Skomra CJ, Ponsky LE, et al. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology 2018;115:39−44.
17. van Gysen K, Kneebone A, Alfieri F, Guo L, Eade T. Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy. J Med Imaging Radiat Oncol 2014;58(4):511−6.
18.Hedrick SG, Fagundes M, Case S, Renegar J, Blakey M, Artz M, et al. Validation of rectal sparing throughout the course of proton therapy treatment in prostate cancer patients treated with SpaceOAR®.J Appl Clin Med Phys 2017;18(1):82−9.
19.Trager M, Greenberger B, Harrison AS, Keller J, Den RB. SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis. J Contemp Brachytherapy 2018;10(6):577−82.
20.Nguyen PL, Devlin PM, Beard CJ, Orio PF 3rd, O’Leary MP, Wolfsberger LD, et al. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy 2013;12(1):77−83.
21.Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O’Farrell DA, O’Leary MP, et al. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy 2014;13(5):442−9.